Retatrutide Research Compound (RT)

"Premium grade Retatrutide validation."

Retatrutide (LY3437943) is a unimolecular triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors, studied as a metabolic research compound. Phase 2 clinical research reported dose-dependent effects on glycemic parameters and body weight in adults with type 2 diabetes (Rosenstock et al., Lancet 2023, PMID 37385280) and in adults with obesity (Jastreboff et al., N Engl J Med 2023, PMID 37366315). Retatrutide research peptide is supplied lyophilized at ≥99% purity verified by HPLC, with identity confirmed by mass spectrometry and a batch-specific Certificate of Analysis (COA) included. Store lyophilized powder at −20 °C, protected from light and moisture. For laboratory research use only — not for human or animal consumption.